Shilpa Medicare Files First Transdermal Patch ANDA with USFDA for Rotigotine
Shilpa Medicare has filed its first transdermal patch ANDA for Rotigotine USP with the USFDA. The product is a generic version of Neupro®, targeting Restless Legs Syndrome and Parkinson's disease. The US market for Rotigotine is estimated at USD 112 million (approx. ₹929 crore).
The filing of a first-of-its-kind product with a major regulatory body like the USFDA, especially for a market estimated at USD 112 million, has a positive but not transformative impact on the company's overall business in the short term. Further approvals and market penetration will determine the long-term impact.
The company has filed its first transdermal patch ANDA with the USFDA, which is a significant milestone and indicates progress in its product development and market expansion strategies.
Shilpa Medicare Limited has announced a significant milestone with the filing of its first Abbreviated New Drug Application (ANDA) for Rotigotine Transdermal System, USP, with the U.S. Food and Drug Administration (USFDA).
This filing marks Shilpa Medicare's inaugural transdermal patch submission to the USFDA. The generic version is for the innovator product Neupro®, and Shilpa's product is pharmaceutical and bioequivalent. The Rotigotine patches are indicated for the treatment of Restless Legs Syndrome and Parkinson's disease. The total addressable US market for Rotigotine is estimated at USD 112 million (approximately ₹929 crore).
The submission originates from the company's finished dosage form manufacturing facility, Shilpa Medicare Ltd, Unit VI, in Dobbaspet, Bengaluru, Karnataka. This facility, approved by European and USFDA authorities, specializes in manufacturing, packaging, labeling, and testing of specialized finished dosage forms like oral dispersible/dissolving films and transdermal patches. This is a complex dosage form, and its successful filing represents a significant achievement for the company.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.